MedTrace Logo

Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA

NCT03119701 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-01-14

Study results available
· View outcomes & findings →

Summary

A study to assess effectiveness and safety of a drug FP-1201-lyo (Recombinant Human Interferon Beta-1a) in the Prevention of Multi-Organ Failure on patients after Open Surgery for a Ruptured Abdominal Aortic Aneurysm

Conditions

  • Preventive Medicine
  • Multi Organ Failure

Interventions

DRUG

Interferon Beta-1A

Lyophilisate for solution for injection.

DRUG

Placebo

Lyophilisate for solution for injection as placebo.

Sponsors & Collaborators

Principal Investigators

  • Harri Hakovirta, MD · Turku University Hospital

  • Maarit Venermo, MD · Helsinki University Central Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-18
Primary Completion
2019-09-23
Completion
2019-10-03

Countries

  • Estonia
  • Finland
  • Lithuania

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03119701 on ClinicalTrials.gov